You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
SBC: Curza Inc Topic: NIAIDProject Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Automated Seizure Detection for Home Seizure Monitoring with Epilog Sensors
SBC: EPITEL, INC. Topic: 105ABSTRACT Aura is a digital health platform that uses Epilog™, a miniature, wireless, wearable EEG sensor worn on the scalp below hairline that can record clinical and subclinical seizures. After an initial diagnosis of epilepsy, an epileptologist will use known information about patients’ seizures to guide the best scalp location to place the Epilog EEG sensor (A). EEG data is continuously tra ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits
SBC: BLACKROCK MICROSYSTEMS, INC Topic: 106ABSTRACT The ability to measure and manipulate local brain circuit activity in living, behaving animals is essential to understanding the complexities of brain function and dysfunction. A novel, penetrating high-density carbon fiber electrode array composed of flexible, ultrathin conductive carbon microfibers was recently developed under the BRAIN Initiative to study neural microcircuit dynamics. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
SBC: SINTX TECHNOLOGIES, INC. Topic: NIAMSPROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
SBC: EXAVIR THERAPEUTICS INC. Topic: NIAIDPROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERS
SBC: Proactive Memory Services Topic: RCUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERSProject Summary/Abstract - ProActive Memory Services, Inc. New strategies are urgently needed to improve Alzheimer’s disease and related dementias (AD/RD) training for 4.6 million professional direct care providers that assist 8.3 million older adults in the US. Assisted living facilities (ALF) and personal care agenc ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SBIR PHASE II, TOPIC 420: INTEGRATED PLATFORM AND CONSUMABLES FOR ROBUST, SENSITIVE AND HIGH-THROUGHPUT SINGLE-CELL PROTEOMICS
SBC: MICROMICS TECHNOLOGIES LLC Topic: 420Mass spectrometry-based proteomics can now quantify up to thousands of proteins from trace samples including single cells, yet such studies require highly specialized, custom-built consumables and instrumentation, and are thus out of reach of most laboratories. Commercial solutions now exist for cell isolation and reagent dispensing at the beginning of the single-cell proteomics (SCP) workflow, an ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CDK2 inhibitors for protecting hearing loss
SBC: TING THERAPEUTICS LLC Topic: NIDCDCDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
REMI Platform for Remote EEG Monitoring
SBC: EPITEL, INC. Topic: NINDSABSTRACT REMI Platform for Remote EEG Monitoring The REMI EEG screening platform. The REMI app running on a medical tablet guides staff through the placement of four Epilog sensors. Epilog transmits EEG through Bluetooth to the app which then relays the data to a cloud server running Persyst EEG reviewing software. An epileptologist logs on to Persyst Mobile to remotely review Epilog EEG in real t ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Preclinical evaluation of an otoprotectant TT002
SBC: TING THERAPEUTICS LLC Topic: NIDCDProject Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health